Cinacalcet hydrochloride (Sensipar).

Article Details

Citation

Copy to clipboard

Poon G

Cinacalcet hydrochloride (Sensipar).

Proc (Bayl Univ Med Cent). 2005 Apr;18(2):181-4.

PubMed ID

16200170 [ View in PubMed

]

Abstract

Currently, >300,000 patients with end-stage renal disease require dialysis. Secondary hyperparathyroidism is a serious complication of end-stage renal disease and can lead to renal osteodystrophy and other organ failure. Vitamin D sterols and phosphate binders are used to treat hyperparathyroidism, but they can cause hypercalcemia, which contributes to vascular and soft-tissue calcification. Cinacalcet (Sensipar) is the first agent in its class that treats secondary hyperparathyroidism by increasing the sensitivity of calcium sensing receptors. It is also indicated for the treatment of hypercalcemia in patients with parathyroid carcinoma. All clinical trials concluded that cinacalcet is effective for the reduction of parathyroid hormone, serum calcium, phosphorus, and calcium-phosphate product levels. Cinacalcet is available as a once-daily oral therapy. Adverse effects are generally mild.

DrugBank Data that Cites this Article

Drug Enzymes

Drug	Enzyme	Kind	Organism	Pharmacological Action	Actions
Cinacalcet	Cytochrome P450 1A2	Protein	Humans	Unknown	Substrate	Details